Bristol Myers Squibb Appoints Cristian Massacesi To Lead A Unified, End-To-End R&D Organization, Effective January 1, 2027

As part of this planned transition, Robert Plenge will remain with Bristol Myers Squibb in an advisory capacity through March 2027 to support a seamless transition before departing the company.

Effective January 1, 2027, the unified R&D organization will bring together Bristol Myers Squibb’s scientific and clinical expertise as one organization, strengthening collaboration from discovery through development. By combining the strengths of its teams, BMS aims to advance its pipeline with greater speed, sharper focus and a shared commitment to delivering for patients.